drugset / Trial / NCT00190931

A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder

NCT00190931

Phase 4 Completed 400 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The overall primary objective of this study is to test the hypothesis that, compared with placebo,administration of atomoxetine will result in an improved work productivity.

Timeline

Start
2003-11
Primary completion
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified